ICU MEDICAL INC quarterly report, Q2 FY2015

Full document

ICU Medical, Inc. — Q2 2015 Form 10-Q

Reporting period: Three and six months ended June 30, 2015. ICU Medical develops, manufactures, and sells medical devices for infusion therapy, oncology, and critical care. Amounts below are in U.S. dollars; financial statement figures are in millions unless noted.

Financial performance and liquidity

  • Q2 revenue: $83.8 million, up 6.5% from $78.7 million. Constant-currency revenue was $86.5 million, up 10%.
  • Q2 earnings: Gross profit was $43.8 million (52.2% margin versus 47.7%); operating income was $20.3 million versus $8.7 million; net income was $13.6 million versus $5.9 million. Diluted EPS was $0.83 versus $0.38.
  • First-half revenue: $165.3 million, up 8.8% from $151.9 million; constant-currency revenue was $170.5 million, up 12%. Gross margin was 52.2% versus 48.4%; operating income was $31.3 million versus $18.6 million; net income was $23.3 million versus $12.5 million. Diluted EPS was $1.43 versus $0.81.
  • Cash flow: First-half operating cash flow was $25.8 million, down from $29.3 million. Investing activities provided $27.1 million, mainly from net investment-security sales; financing activities provided $8.8 million. Cash and cash equivalents ended at $331.1 million, up from $275.8 million at year-end 2014.
  • Liquidity and debt: Cash, cash equivalents, and investment securities totaled $367.3 million, versus $346.8 million at December 31, 2014. The balance sheet reports no borrowings or debt; current liabilities were $28.7 million. Management said existing liquidity and expected operating cash flow should fund operations for at least 12 months.
  • Other metrics: Total assets were $570.2 million and stockholders’ equity was $538.1 million. Foreign-currency translation reduced first-half comprehensive income; accumulated other comprehensive loss was $17.8 million.

Changes versus the prior comparable period

  • Q2 sales growth was led by infusion therapy (+6%) and oncology (+12%); critical care increased 4%. First-half infusion therapy grew 11%, oncology 6%, and critical care 1% as reported.
  • Management attributed higher gross margin to favorable customer and product mix and operational efficiencies. Lower SG&A reflected reduced sales and marketing costs following the 2014 U.S. sales reorganization and currency effects; R&D spending also declined.
  • First-half operating results included a $7.1 million legal settlement charge. The lower first-half effective tax rate—27% versus 34%—reflected tax credits, deductions, and benefits related to tax examinations and tax-reserve estimates.
  • Operating cash flow declined despite higher net income, with working-capital and tax-payment movements affecting cash generation. Cash and investments increased overall, aided by net sales of investment securities.

Outlook, risks, and unusual items

  • Management estimated 2015 capital expenditures of approximately $12–14 million, principally for manufacturing equipment and molds in the U.S. and Mexico and information technology. Actual spending may differ.
  • Hospira remains a major customer and strategic distribution partner: it represented 35% of Q2 revenue and 36% of first-half revenue, and 31% of accounts receivable at June 30. Its agreements extend through most of 2018. ICU Medical warned that a deterioration in the relationship, Hospira’s market position, or customer demand could adversely affect results.
  • An April 2015 arbitration awarded Hospira C$8.2 million (reported as $6.5 million) plus 75% of its legal fees and expenses. ICU Medical paid $7.5 million in Q2; management said the ruling was not expected to significantly affect future earnings.
  • Foreign exchange is a risk: approximately 14% of Q2 and first-half revenue was denominated in euros, and the company does not hedge its foreign-currency exposures. Management cited potential sensitivity of balance-sheet net assets to euro movements.
  • Other risks include customer concentration, competitive and pricing pressures, product development and regulatory outcomes, raw-material costs, and market or production disruptions. The filing reported no material change to previously disclosed risk factors and no material adverse impact expected from other routine legal proceedings.
  • The company had $29.8 million of cash held by foreign subsidiaries and expected to reinvest it outside the U.S. The filing also disclosed $22.5 million remaining under its authorized share-purchase plan; no shares were purchased under the plan in Q2.

Important facts for investors to verify

  • Whether sales growth, margin improvement, and operating efficiencies persist, particularly after excluding currency effects and the settlement charge.
  • Hospira’s continuing share of revenue and receivables, the status and terms of its distribution agreements, and any post-settlement effects on commercial relations.
  • Cash conversion and working-capital trends, including receivables, inventory, and tax-payment timing.
  • Execution and cost of the planned $12–14 million in 2015 capital expenditures, and whether cash and investments remain sufficient under adverse conditions.
  • Foreign-exchange exposure, including euro balances and the absence of hedging, as well as the tax implications of any future repatriation of foreign cash.